





## 2<sup>nd</sup> CANADIAN CLL MEETING Inn at the Forks Winnipeg, Manitoba November 4 & 5, 2006

### **AGENDA**

### Saturday, November 4, 2006

Keynote Address Role of VEGF in the Pathogenesis of CLL Neil Kay Mayo Clinic, Rochester, MN
Welcome Address James Johnston
Breakfast

#### Session I – Basic Research in CLL Chair: Dr. Spencer Gibson

	Chair: Dr. Spencer Gibson
9:30 – 9:50 am	CLL, Bcl-? and apoptosis: The View from the Hole Brian Leber
9:50 – 10:10 am	Coffee Break
10:10 – 10:30 am	DNA Repair in CLL Raquel Aloyz
10:30 – 10:50 am	LPA as a Survival Factor in CLL Spencer Gibson
10:50 – 11:50 am	Discussion Period
12:00 – 1:00 pm	Lunch



## Session II – Clinical Trials Chair: James Johnston

1:00 – 1:20 pm	Upcoming NCIC Clinical Trials in CLL Steve Couban
1:20 – 1:40 pm	Proposed Phase II Clinical Trial Using Valproic Acid as an HDAC Inhibitor in CLL David Szwajcer
1:40 – 2:00 pm	Phase II Clinicial trial Using Revlimid in CLL Christine Chen
2:00 – 2:20	A Phase I/II Study Investigation Multiple Injections of CLL-CDV01 (Autologous CD 14-derived DCs Coelectroporated with Total Tumour RNA and Human CD40L RNA) in Patients with Previously Treated CLL Graeme Fraser
2:20 – 2:40 pm	Coffee
2:40 – 3:00 pm	Alemtuzumab for Consolidation Following Fludarabine/ Rituximab in CLL Joe Connors
3:00 – 3:20 pm	Epidemiology of CLL in Manitoba/CLL Tumor Bank <i>Matthew Seftel</i>
3:20 – 4:20 pm	Discussion Period
4:30 – 6:00 pm	Translational Research Proposal: "Prognostic Markers and Marrow SCT for CLL in Canada" Chairs: Spencer Gibson & Matthew Seftel Spencer Gibson will outline new federal funding opportunities for translational research initiatives. This will be followed with a discussion about the possibility of developing a uniform Canadian SCT transplant protocol for CLL tied in with the measurement of a variety of prognostic markers.
7:00 pm	Dinner The Current Restaurant Inn at the Forks

# Sunday, November 5, 2006

8:00 – 8:30 am Breakfast

### Session III – Stem Cell Marrow Transplantation in CLL Chair: Matthew Seftel University of Manitoba

University of Manitoba		
8:30 – 9:30 am	IgVH Gene Mutational Analysis in CLL Diane Jelinek Mayo Clinic, Rochester, MN	
9:30 – 9:50 am	Measurement of ZAP-70 and its Utility in CLL Carmen Morales	
9:50 – 10:10 am	Allogeneic SCT for CLL in BC Cynthia Toze	
10:10 – 10:30 am	Allogeneic SCT for CLL in Alberta  Michelle Geddes	
10:30 – 10:50 am	Coffee	
10:50 – 11:10 am	Allogeneic SCT for CLL at the Princess Margaret Hospital, Toronto John Kuruvilla	
11:10 – 11:30 am	Allogeneic SCT for CLL in Montreal Sandra Cohen	
11:30 am – 12:00 pm	Discussion Period	
12:00 – 12:15 pm	Concluding Remarks	
12:15 pm	Lunch	